Vir Biotechnology launches public stock offering following ECLIPSE 1 Phase 3 resultsNov 12Clinical readoutVir Biotechnology, Inc.Updated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Vir reports Week 96 SOLSTICE data, ECLIPSE program fully enrolled, VIR-5500 expansion underwayAug 5Quarterly updateVir Biotechnology, Inc.VIR-5500